CD3 × CD19 T-biAb blinatumomab (Blincyto; Amgen, Inc.)was approved by the FDA and EMA for the treatment of adults and children with refractory or relapsed (R/R) pre-B cell acute withlymphoblastic leukemia (pre-B-ALL) [159], and approved for the treatment of adults and children with pre-B ALL in first or second complete remission with minimal residual disease [160,161]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.